Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2023-04-12 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
112年3月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (美時) providing details on fund loans and endorsement guarantees for the current and previous month, including limits and balances. It is a short report (631 characters) focused on specific financial data related to loans and guarantees, without comprehensive financial statements or management discussion. It does not present a full annual or interim report, nor is it an announcement of a report publication. The content fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure of financial information that does not fit into other specific categories like Annual Report, Interim Report, or Capital Update.
2023-04-12 Chinese
112年3月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時 (Mei Shi) for the period of March 2023 (民國112年03月). It includes comparative figures from the previous year and percentage changes. The document is very short (780 characters) and contains no detailed financial statements, management discussion, or comprehensive analysis. It appears to be a brief financial data disclosure rather than a full financial report or earnings release. There is no indication of a conference call transcript, AGM materials, or regulatory certifications. The document is essentially a regulatory disclosure of revenue figures, typical of a general regulatory announcement or compliance filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement of financial data without substantive financial report content.
2023-04-12 Chinese
112年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and other executives. It includes data on shares held, increases, decreases, and trust shares, with specific references to insider identities and their share transactions. There is no indication of financial statements, earnings data, or management discussion. The content is focused on insider share transactions and holdings. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed insider shareholding data, not just an announcement or summary. Therefore, the appropriate classification is DIRS.
2023-04-10 Chinese
112年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors, supervisors, and senior management. It lists share counts, pledged shares, and related ratios for various insiders and their related parties. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. There is no indication of a report or announcement of voting results, dividends, or capital changes. The document is not a narrative or transcript but a structured disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or holdings by company directors and executives. The document length is 4348 characters, which is sufficient for a detailed insider shareholding report. Therefore, the appropriate classification is DIRS with high confidence.
2023-04-10 Chinese
111年度財務比率
Fund Information / Factsheet Classification · 95% confidence The document contains a financial data analysis summary for the company 美時 over three fiscal years (109年度, 110年度, 111年度). It includes various financial ratios and performance metrics such as debt to asset ratio, liquidity ratios, turnover rates, profitability ratios, and cash flow ratios. The document is concise (1006 characters) and presents summarized financial data rather than a full detailed report. There is no indication that this is a full annual or interim report, nor is it an announcement or certification. The content resembles a brief financial factsheet summarizing key financial metrics over multiple years, which aligns with the definition of Fund Information / Factsheet (FS).
2023-03-31 Chinese
111年第4季海外子公司投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment holdings and investment income/losses related to overseas subsidiaries for a specific quarter (111年4季, which corresponds to Q4 of the 111th year in the Taiwanese calendar). It includes financial figures such as original investment amounts, investment balances, and recognized investment gains or losses. The document is relatively short (2488 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a certification or announcement but a detailed financial disclosure. Given the nature of the content and the context (Taiwanese public company disclosure), this fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement of investment information that does not fit into other specific categories like Annual Report or Interim Report. The document does not contain comprehensive financial statements or management discussion, so it is not an IR or 10-K. It is not a report publication announcement since it contains substantive data, not just a notice. Therefore, the best classification is Regulatory Filings (RNS).
2023-03-31 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.